Advancements in the Management of Gynecological Cancers: ESMO 2024 - Episode 7
Antibody-Drug Conjugates in Ovarian Cancer: Emerging Data and Treatment Integration
Panelists discuss recent data on various antibody-drug conjugates (ADCs) in ovarian cancer, including mirvetuximab soravtansine from trials like FORWARD II, MIRASOL, and PICCOLO; luveltamab tazevibulin and rinatabart sesutecan from STRO-002-GM1 and REFRαME-O1; and raludotatug deruxtecan from REJOICE-Ovarian01, highlighting the evolving role of these agents in the treatment landscape for ovarian cancer.
Video content above is prompted by the following:
- Briefly comment on recent data surrounding other antibody-drug conjugates in ovarian cancer and discuss the evolving role of these agents in the treatment landscape.
- Mirvetuximab soravtansine (anti-FR)
- FORWARD II; MIRASOL; PICCOLO
- Luveltamab tazevibulin (anti-FR), rinatabart sesutecan (Rina-S)
- STRO-002-GM1; REFRαME-O1
- Rina-S
- Raludotatug deruxtecan (R-DXd, anti-CDH6)
- REJOICE-Ovarian01
Related Content:
